4-Pyridone Derivatives as HIV Integrase Inhibitors
Solution Overview
Problem
Current antiviral compounds for HIV infection, particularly HIV integrase inhibitors, have limitations in effectively inhibiting HIV replication and treating or preventing HIV infection, necessitating the development of new compounds that can target HIV integrase more effectively.
Innovation Solution
The development of 4-Pyridone Compounds, specifically those of Formula (I), which can inhibit HIV viral replication by targeting HIV integrase, offering a new approach for treating or preventing HIV infection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing HIV integrase inhibitors are used, then HIV replication can be inhibited, but the inhibition effectiveness is limited and insufficient for effective treatment or prevention
Solution Approach 1:
The patent modifies the chemical structure parameters of integrase inhibitors by introducing a 4-pyridone core with specific substituents (R1, R2, R3, R4 groups) and linkers (A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, U, V, W, X, Y, Z), thereby changing the molecular properties to achieve improved inhibitory activity against HIV integrase while maintaining drugability
Solution Approach 2:
The patent creates composite molecular structures by combining the 4-pyridone core with various functional groups and linkers to form new integrase inhibitor compounds that exhibit enhanced antiviral activity compared to existing inhibitors, effectively addressing the limitation of current treatment options
Data Source
AI summary
The present invention relates to 4-Pyridone Compounds of Formula (I); and pharmaceutically acceptable salts and prodrugs thereof, wherein A, R1, R2, and R3 are as defined herein. The present invention also relates to compositions comprising at least one 4-Pyridone Compound, and methods of using the 4-Pyridone Compounds for treating or preventing HIV infection in a subject or the clinical manifestations thereof.



